NuSep tries NxGen
Thursday, 02 October, 2008
Bioseparations company NuSep [ASX: NSP] has reached a binding agreement to acquire NxGen Pharmaceuticals for $25 million.
Pending shareholder approval, NuSep will acquire all of NxGen in exchange for 294 million NuSep shares valued at 8.5c each.
This represents 87.5 per cent of NuSep's expanded capital and 10 times NxGen's net profit forecast for this financial year.
NxGen is a custom pharmaceuticals manufacturer and formulator, with products including an erectile dysfunction nasal spray it makes for a medical clinic.
How does the brain evaluate rewards?
Neuroscientists have shown how nerve cells in the amygdala not only encode the probability and...
Breakthrough drug prevents long COVID symptoms in mice
Mice treated with the antiviral compound were protected from long-term brain and lung dysfunction...
Antibiotics hinder vaccine response in infants
Infants who received antibiotics in the first few weeks of life had significantly lower levels of...
